Collaborating Clinics Damage Index score (SDI). Internal consistency and test-retest reliability, convergent and discriminant validity were examined.

Results: 328 Russian SLE patients were enrolled in the study (MF 30:298, mean age 34.4±11.5 years, mean disease duration 106.9±7.9 months; mean SLEDAI 2K 9.6±8.0, mean SDI 0.2±0.6). The LupusQoL-Russian demonstrated substantial evidence of construct validity. Each domain showed good correlation when compared with equivalent domains of the SF-36 (p<0.001 for all comparisons), LupusQoL-Russian discriminated between patients with different degrees of disease activity according to SLEDAI 2K. LupusQoL domains showed a trend to lower values in patients with higher disease activity (SLEDAI 2K>4) compared with those with lower disease activity (SLEDAI 2K<4), reaching statistically significant difference when considering the domains “Physical health”, “Planning”, “Fatigue” and “Body image” (p=0.007, p=0.0004, p=0.003 and p=0.007, respectively).

LupusQoL-Russian was significantly lower for “Physical health”, “Planning” and “Fatigue” in patients with SDI 1 (p<0.002, p=0.03, and p=0.03 respectively) (table 1). Test-retest reliability was good to excellent between baseline and day 3 (intraclass correlation coefficient (ICC) 0.7–0.9).
Abstract FRIO359 – Figure 1. Ln (natural log) odds ratio for damage transition vs time-adjusted mean of laboratory variables. Red region (95% CI) lying above the y=0 line indicates the risk is statically significant (p<0.05). Regression lines (blue) suggest the risk of damage increase is approximately proportional with the distance from normal pathology measure range.

Conclusions: Routine pathology measures were found to be proportionally associated with organ damage risk in SLE. The potential for the use of these measures as biomarkers, for example to generate an organ damage risk calculator for SLE, warrants further research.

Disclosure of Interest: None declared


FRIO360 DISEASE SEVERITY OF PROLIFERATIVE LUPUS NEPHRITIS IN MAGHREBIANS

F. Tamirou1, N. Costedoat-Chalumeau2, G. Medkouri2, E. Daugas3, E. Hachulla4, N. Jourde-Chiche5, A. Karras1, V. le Guen4, V. Gennemi6, M. Jadoul7, F. A. Houssiau1. 1Rheumatology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium; 2Internal Medicine Department, Centre de référence des maladies auto-immunes et systémiques rares d’Ile de France, AP-HP, Hôpital Cochin, Université Descartes-Sorbonne, Paris, France; 3Nephrology Department, Centre Hospitalier Universitaire Ibn Rochid, Casablanca, Morocco; 4Nephrology Department, AP-HP, Hôpital Bichat, Université Paris Diderot, Paris; 5Internal Medicine Department, Hôpital Claude Huriez, Université Lille Nord, Lille; 6Nephrology Department, AP-HM, Hôpital de la Conception, Aix-Marseille Université, Marseille; 7Nephrology Department, AP-HP, Hôpital Européen Georges-Pompidou, Université Paris Descartes; 8Internal Medicine Department, Centre de référence des maladies auto-immunes et systémiques rares d’Ile de France, AP-HP, Hôpital Cochin, Université Paris Descartes-Sorbonne, Paris; 9Pathology Institute, Université Lille Nord, Lille, France; 10Nephrology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgium

Background: The negative influence of African-American ethnicity on the prognosis of lupus nephritis (LN) is well known but – to the best of our knowledge – the impact of Maghrebian ethnicity has never been evaluated, although the disease is purported to be quite prevalent and severe in North Africa.

Objectives: To study the influence of Maghrebian ethnicity on the clinical and pathological presentation of LN, the renal relapse rate, the renal and overall survival and the predictive value of an early proteinuria decrease for good long-term renal outcome in this population compared to native Europeans.

Methods: We retrospectively reviewed the files of an inception cohort of 194 patients with proliferative LN followed in 7 lupus centres belonging to 3 groups: Europeans living in Belgium/France (E; n=111), Maghrebians living in Europe, in casu Belgium/France (ME; n=43) and Maghrebians living in Morocco (MM; n=40). Baseline presentation was compared between these 3 groups but complete long-term outcome data were available only for E and ME patients.

Results: At presentation, clinical (gender, age, nephritic syndrome, serum creatinine, eGFR, UPCR ratio) and pathological (ISN/RPS class) characteristics of LN did not differ between E, ME and MM patients. At one year, renal remission was met in 73%, 63% and 68% in E, ME and MM patients, respectively. Achievement of a target proteinuria below 0.7 g/day one year after treatment initiation was 76%, 63% and 68%, respectively. Nevertheless, while proteinuria measured at month 12 accurately predicted a serum creatinine value <1 mg/dl at 7 years in E patients, this was not the case in the ME group, in whom serum creatinine at month 12 performed better. Renal relapses were more common in ME patients (54%) than in E patients (29%) (p<0.01). Time to renal flare and to ESRD was shorter in ME patients compared to E patients (p<0.0001 and p<0.05, respectively) as shown in figure 1. At last follow-up, mean proteinuria, serum creatinine and eGFR did not differ between E and ME patients, nor did the percentage of patients who died or suffered from ESRD or permanent renal impairment.

Conclusions: Despite a similar disease profile at onset, the prognosis of LN is more severe in Maghrebians living in Europe compared to native Europeans, with a higher relapse rate and a shorter time to ESRD.

Disclosure of Interest: None declared


FRIO361 PREGNANCY OUTCOMES AND THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM OUR 30 YEARS’ EXPERIENCE PREGNANCY CLINIC

F. Crisalli1, M.G. Lazzaroni1, L. Andreoli1, M.C. Gerardi1, L. Antolini1, G. Parma2, C. Benigno2, A. Lojacono2, S. Zatti2, V. Cappa3, S. Calzà3, F. Franceschini1, A. Tincani4. 1U.O. Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia; 2U.O. Rheumatology and Clinical Immunology, Federico II University Hospital and University of Napoli, Napoli; 3Obstetrics and Gynecology Unit; 4Biostatistics and Biomathematics Unit and Bioinformatics Unit, Spedali Civili and University of Brescia, Brescia, Italy

Background: The outcome of Systemic Lupus Erythematosus(SLE) pregnancies has dramatically improved thanks to pregnancy planning, multidisciplinary management and close monitoring during pregnancy. In our experience, programmed pregnancies in SLE patients had similar rates of pregnancy losses as compared to general obstetric population, but there are still open issues on some pregnancy complications that more frequently affect SLE patients.

Objectives: To analyse the obstetric outcome of SLE patients, according to specific therapy received during pregnancy.

Methods: A monocentric, retrospective study of 98 SLE patients with a total of 134 pregnancies followed prospectively by multidisciplinary team(1987–2015). Adverse Pregnancy Outcomes (APOs) were defined as one of the following: premature miscarriage(<10th week), intrauterine fetal death(>10 th week), perinatal death(<30 th day of life), severe preterm birth(<34 th week) and preterm birth (between 34th-36th weeks). We also evaluated the frequency of other pregnancy complications such as preterm premature rupture of membranes(pPROM) and pre-eclampsia (PE).

Results: Among the 134 pregnancies(including 3 twin pregnancies), flares occurred in 10 (7.5%) and APOs in 39 (29.1%) cases (table 1). pPROM complicated 9 pregnancies, all resulted in preterm deliveries, including 3 severe preterm birth; PE complicated 6 pregnancies resulting in 2 preterm birth, 1 intrauterine fetal death, 1 perinatal death and 2 term birth. The rates of APOs, pPROM and PE were compared according to receiving or not a specific therapy: hydroxychloroquine(HCQ), low dose aspirin(LDA), immunosuppressant(IS) during the overall pregnancy and corticosteroids(35 mg/week) during the 1st, 2nd and the 3rd trimester. No statistical significant association was found between a specific therapy and the rate of PE. HCQ and LDA did not significantly affect the rate of APOs or pPROM while pregnancies exposed to IS showed a higher frequency of APOs(47% vs 20%, p=0.003), in particular premature miscarriages(16% vs 2%, p=0.007). Pregnancies exposed to CS had higher frequency of preterm birth(1 st trimester 44% vs 28%, p=0.015; 2nd trimester 36% vs 13% p=0.004; 3rd trimester 34% vs 14%, p=0.019). Considering only the 120 pregnancies resulted in live birth, those exposed to CS had higher frequency of preterm birth(1 st trimester p=0.008; 2nd trimester p=0.032; 3rd trimester p=0.011) (table 2). In particular, pregnancies exposed to CS in the 1 st trimester had higher frequency of preterm birth on 34th-36th w (p=0.017), while pregnancies exposed in the 3rd trimester had a higher frequency of preterm birth before 34th w(p=0.038). Furthermore, a higher frequency of pPROM was observed in those exposed to CS(1 st trimester p=0.001; 2nd trimester p=0.003; 3rd trimester p=0.001).